Pharma News

Keep updating your pharma knowledge
19 Jan 2015

Novo Nordisk launches diabetes drug Ryzodeg in India

Denmark based pharmaceutical firm Novo Nordisk today launched it’s combination diabetic drug Ryzodeg, priced at Rs 1,595 for 300 units, for people with type II diabetes in India.

Apart from India, Ryzodeg has been approved for marketing in Aruba, Brazil, Chile, Costa Rica, El Salvador, EU, Hong Kong, Iceland, Israel, Japan, Kazakhstan, Macedonia, Mexico, Norway, Russia, South Korea and Switzerland, Novo Nordisk said.

Novo Nordisk Corporate VP for Business Area Africa, Gulf & India, Mads Bo Larsen said: “India has close to 65.1 million people with diabetes standing second in the world map….We are extremely pleased to have introduced Ryzodeg reinforcing our commitment to provide best of healthcare solutions for the use of doctors in India.”

Ryzodeg® is the intended brand name for insulin degludec/insulin aspart, which contains the new-generation basal insulin degludec in a formulation with a bolus boost of insulin aspart. Ryzodeg® is the first and only soluble insulin combination of ultra-long-acting insulin degludec and the most prescribed rapid-acting insulin, NovoRapid® (NovoLog®in the US), providing both fasting and post-prandial glucose control.

Courtesy: Economic Times. Read full article.

 

Leave a Reply


The reCAPTCHA verification period has expired. Please reload the page.

Upskill Your Pharma Knowledge

Explore Next Gen Learning

Case Studies & Caselets | Simulation Based Learning | E-Lectures | Online Self Competency Assessments

Thank You for Subscription!